Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents

被引：2
|
作者：
Cook, G. [1 ]
机构：
[1] Univ Leeds, Dept Haematol, Transplant Immunol Grp, Sect Expt Haematol,Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
来源：
BONE MARROW TRANSPLANTATION | 2015年 / 50卷 / 10期
关键词：
HIGH-DOSE MELPHALAN; BORTEZOMIB; DEXAMETHASONE; THERAPY; PHASE-2; RELAPSE; TRIAL;
D O I：
10.1038/bmt.2015.175
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1269 / 1270
页数：2
相关论文
共 25 条
  • [1] Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Agents
    Shimazaki, Chihiro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (01) : 14 - 15
  • [2] The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma
    Miller, Kevin C.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Lacy, Martha Q.
    Dispenzieri, Angela A.
    Dingli, David
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Muchtar, Eli
    Hogan, William J.
    Kumar, Shaji K.
    BONE MARROW TRANSPLANTATION, 2019, 54 (12) : 2039 - 2050
  • [3] Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents
    Merz, M.
    Neben, K.
    Raab, M. S.
    Sauer, S.
    Egerer, G.
    Hundemer, M.
    Hose, D.
    Kunz, C.
    Heiss, C.
    Ho, A. D.
    Goldschmidt, H.
    Hillengass, J.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 189 - 195
  • [4] Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents
    Tremblay, D.
    Lancman, G.
    Moshier, E.
    Bar, N.
    Jagannath, S.
    Chari, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 (10) : 1468 - 1470
  • [5] Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies
    Parrondo, Ricardo D.
    Ailawadhi, Sikander
    Sher, Taimur
    Chanan-Khan, Asher A.
    Roy, Vivek
    JCO ONCOLOGY PRACTICE, 2020, 16 (02) : 56 - +
  • [6] Is There an Optimal Timing of Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Agents?
    Toprak, Selami Kocak
    TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (03) : 338 - 339
  • [7] The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs
    Wan, Xixi
    Yu, Tian
    Yu, Tao
    Cai, Huili
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [8] Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents
    Mizuno, Shohei
    Kawamura, Koji
    Hanamura, Ichiro
    Sunami, Kazutaka
    Mori, Takehiko
    Nakamura, Fumihiko
    Iida, Shinsuke
    Nakazawa, Hideyuki
    Makita, Masanori
    Kako, Shinichi
    Sawa, Masashi
    Ueda, Yasunori
    Takahashil, Hiroyuki
    Kanda, Yoshinobu
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Takamatsu, Hiroyuki
    Takami, Akiyoshi
    BONE MARROW TRANSPLANTATION, 2019, 54 (10) : 1595 - 1604
  • [9] Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma
    Zannetti, Beatrice Anna
    Tacchetti, Paola
    Pantani, Lucia
    Gamberi, Barbara
    Tosi, Patrizia
    Rocchi, Serena
    Cellini, Claudia
    Ronconi, Sonia
    Pezzi, Annalisa
    Mancuso, Katia
    Rizzello, Ilaria
    Caratozzolo, Isola
    Martello, Marina
    Dozza, Luca
    Cavo, Michele
    Zamagni, Elena
    ANNALS OF HEMATOLOGY, 2017, 96 (12) : 2071 - 2078
  • [10] Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma
    Lee, Sung-Eun
    Yoon, Jae-Ho
    Shin, Seung-Hwan
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong-Wook
    Min, Woo-Sung
    Park, Chong-Won
    Min, Chang-Ki
    ANNALS OF HEMATOLOGY, 2014, 93 (04) : 627 - 634
123